Sign In
Buy IGC
$0.268
+0.0079 (+3.04%)
At Close: Jul 20, 2026
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
09:00am, Thursday, 19'th Mar 2026
- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developi
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Short Interest Up 15.9% in February
04:15am, Thursday, 19'th Mar 2026
IGC Pharma, Inc. (NYSEAMERICAN:IGC - Get Free Report) was the recipient of a large increase in short interest in February. As of February 27th, there was short interest totaling 675,735 shares, an inc
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
09:00am, Wednesday, 18'th Mar 2026
POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
08:30am, Thursday, 26'th Feb 2026
POTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's diseas
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
08:30am, Tuesday, 24'th Feb 2026
POTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity re
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
08:30am, Monday, 23'rd Feb 2026
- Practice integrated neurology network expands enrollment capacity - POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today ann
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
08:30am, Tuesday, 17'th Feb 2026
POTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
08:30am, Thursday, 12'th Feb 2026
POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating i
IGC Pharma Announces Equity Research Update by Alliance Global Partners
08:30am, Tuesday, 10'th Feb 2026
POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
08:30am, Monday, 09'th Feb 2026
- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst - POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
08:30am, Monday, 02'nd Feb 2026
POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
09:00am, Thursday, 22'nd Jan 2026
- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE Ameri
- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (N
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
08:00am, Tuesday, 06'th Jan 2026
POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligen
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
09:00am, Monday, 05'th Jan 2026
- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC
